BiomX Inc. has decided to discontinue the BX004 Cystic Fibrosis Phase 2b trial based on internal analysis and DMC feedback. The company remains optimistic about the BX011 phage program for S. aureus infections in diabetic foot infections and is implementing cost-cutting measures while exploring strategic options. The decision to end the CF trial was due to high rates of adverse events, with resources needed for an alternative dosing strategy beyond what was available. BiomX will now focus on developing bacteriophage-based therapeutics, including BX011 for S. aureus infections.

Read more at GlobeNewswire: BiomX Announces Discontinuation of Phase 2b BX004 Trial